Among our signatures, SH3 domain-containing protein 21 (SH3D21) might serve as a target to improve the effects of gemcitabine in the treatment of pancreatic cancer (Masoudi et al., 2019). This evidence concerns the gene MNMIP1 and pancreatic neoplasm.